학술논문
Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2− breast cancer in Mexico
Document Type
Article
Author
Source
In: Clinical and Translational Oncology . (Clinical and Translational Oncology, January 2024, 26(1):239-244)
Subject
Language
English
ISSN
16993055
1699048X
1699048X